This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Treatment

Authoring team

Investigations are similar to those for hydatidiform mole with in addition, CT scans of the abdomen, pelvis and head for possible metastasis.

Treatment usually entails evacuation of the uterus followed by chemotherapy. Hysterectomy may be indicated if the patient is over 40 years of age.

The chemotherapeutic regime adopted is determined by the presence of metastatic disease. It normally includes cycles of methotrexate, actinomycin-D or cyclophosphamide.

Radiotherapy may also be indicated in patients with disease metastatic to the brain or liver.

The level of beta-hCG should be monitored monthly. For patients without metastases, follow-up is usually for 2 years. If metastatic disease was present, monitoring may be necessary for up to 5 years, usually on a quarterly basis after the initial two years.

Patients with primary tumours alone show a 90% success rate; this falls to 40-75% in those with metastatic disease.


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.